559 related articles for article (PubMed ID: 17975151)
1. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
2. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
3. Multipeptide vaccination in cancer patients.
Pilla L; Rivoltini L; Patuzzo R; Marrari A; Valdagni R; Parmiani G
Expert Opin Biol Ther; 2009 Aug; 9(8):1043-55. PubMed ID: 19591629
[TBL] [Abstract][Full Text] [Related]
4. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
5. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.
Pullarkat V; Lee PP; Scotland R; Rubio V; Groshen S; Gee C; Lau R; Snively J; Sian S; Woulfe SL; Wolfe RA; Weber JS
Clin Cancer Res; 2003 Apr; 9(4):1301-12. PubMed ID: 12684398
[TBL] [Abstract][Full Text] [Related]
7. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
8. Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
Reynolds SR; Zeleniuch-Jacquotte A; Shapiro RL; Roses DF; Harris MN; Johnston D; Bystryn JC
Clin Cancer Res; 2003 Feb; 9(2):657-62. PubMed ID: 12576432
[TBL] [Abstract][Full Text] [Related]
9. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
Appay V; Voelter V; Rufer N; Reynard S; Jandus C; Gasparini D; Lienard D; Speiser DE; Schneider P; Cerottini JC; Romero P; Leyvraz S
J Immunother; 2007; 30(2):240-50. PubMed ID: 17471171
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
[TBL] [Abstract][Full Text] [Related]
11. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.
Filipazzi P; Pilla L; Mariani L; Patuzzo R; Castelli C; Camisaschi C; Maurichi A; Cova A; Rigamonti G; Giardino F; Di Florio A; Asioli M; Frati P; Sovena G; Squarcina P; Maio M; Danielli R; Chiarion-Sileni V; Villa A; Lombardo C; Tragni G; Santinami M; Parmiani G; Rivoltini L
Clin Cancer Res; 2012 Dec; 18(23):6485-96. PubMed ID: 23032742
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
[TBL] [Abstract][Full Text] [Related]
14. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
15. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan.
Kitano S; Kageyama S; Nagata Y; Miyahara Y; Hiasa A; Naota H; Okumura S; Imai H; Shiraishi T; Masuya M; Nishikawa M; Sunamoto J; Akiyoshi K; Kanematsu T; Scott AM; Murphy R; Hoffman EW; Old LJ; Shiku H
Clin Cancer Res; 2006 Dec; 12(24):7397-405. PubMed ID: 17189412
[TBL] [Abstract][Full Text] [Related]
16. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.
Salazar LG; Fikes J; Southwood S; Ishioka G; Knutson KL; Gooley TA; Schiffman K; Disis ML
Clin Cancer Res; 2003 Nov; 9(15):5559-65. PubMed ID: 14654536
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients.
Bins A; Mallo H; Sein J; van den Bogaard C; Nooijen W; Vyth-Dreese F; Nuijen B; de Gast GC; Haanen JB
J Immunother; 2007; 30(2):234-9. PubMed ID: 17471170
[TBL] [Abstract][Full Text] [Related]
18. Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH
Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266
[TBL] [Abstract][Full Text] [Related]
19. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
[TBL] [Abstract][Full Text] [Related]
20. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]